IDenta Corp. (IDTA)
USD 0.45
(0.0%)
USD 0.45
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.05 Million USD | -21.45% |
| 2022 | 1.33 Million USD | -3.83% |
| 2021 | 1.39 Million USD | -3.98% |
| 2020 | 1.44 Million USD | 43.15% |
| 2019 | 1.01 Million USD | 22.47% |
| 2018 | 826.97 Thousand USD | 99.14% |
| 2017 | 415.27 Thousand USD | 0.69% |
| 2016 | 412.42 Thousand USD | -42.44% |
| 2015 | 716.53 Thousand USD | 67.0% |
| 2014 | 429.07 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 360.98 Thousand USD | -15.73% |
| 2024 Q1 | 428.34 Thousand USD | -6.84% |
| 2023 FY | 1.05 Million USD | -21.45% |
| 2023 Q4 | 459.81 Thousand USD | 165.1% |
| 2023 Q3 | 173.45 Thousand USD | -7.98% |
| 2023 Q1 | 231.62 Thousand USD | -41.66% |
| 2023 Q2 | 188.49 Thousand USD | -18.62% |
| 2022 Q2 | 378.98 Thousand USD | 49.57% |
| 2022 FY | 1.33 Million USD | -3.83% |
| 2022 Q4 | 397.05 Thousand USD | 19.49% |
| 2022 Q3 | 332.29 Thousand USD | -12.32% |
| 2022 Q1 | 253.38 Thousand USD | -20.19% |
| 2021 Q3 | 335.12 Thousand USD | -13.41% |
| 2021 Q2 | 387.04 Thousand USD | 9.88% |
| 2021 FY | 1.39 Million USD | -3.98% |
| 2021 Q4 | 317.46 Thousand USD | -5.27% |
| 2021 Q1 | 352.24 Thousand USD | 51.5% |
| 2020 Q4 | 232.5 Thousand USD | -53.13% |
| 2020 FY | 1.44 Million USD | 43.15% |
| 2020 Q1 | 227.57 Thousand USD | 142.55% |
| 2020 Q2 | 495.66 Thousand USD | 117.81% |
| 2020 Q3 | 496.1 Thousand USD | 0.09% |
| 2019 Q3 | 381.55 Thousand USD | 11.24% |
| 2019 Q1 | 197.38 Thousand USD | 14.31% |
| 2019 FY | 1.01 Million USD | 22.47% |
| 2019 Q4 | 93.82 Thousand USD | -75.41% |
| 2019 Q2 | 342.98 Thousand USD | 73.77% |
| 2018 Q3 | 260.18 Thousand USD | 5.49% |
| 2018 FY | 826.97 Thousand USD | 99.14% |
| 2018 Q4 | 172.67 Thousand USD | -33.64% |
| 2018 Q2 | 246.65 Thousand USD | 64.26% |
| 2018 Q1 | 150.16 Thousand USD | 30.87% |
| 2017 FY | 415.27 Thousand USD | 0.69% |
| 2017 Q1 | 131.65 Thousand USD | 0.0% |
| 2017 Q2 | 83.49 Thousand USD | -36.58% |
| 2017 Q3 | 84 Thousand USD | 0.6% |
| 2017 Q4 | 114.73 Thousand USD | 36.59% |
| 2016 FY | 412.42 Thousand USD | -42.44% |
| 2015 FY | 716.53 Thousand USD | 67.0% |
| 2014 FY | 429.07 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -15.18% |
| Arrayit Corporation | 4.37 Million USD | 75.976% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 95.933% |
| Bioqual, Inc. | 58.59 Million USD | 98.205% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 93.125% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.986% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 83.482% |
| iMD Companies, Inc. | - USD | -Infinity% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 97.385% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -134.993% |
| InVitro International | 792.62 Thousand USD | -32.671% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 90.553% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 85.444% |
| NovelStem International Corp. | 12 Thousand USD | -8663.25% |
| Optigenex Inc. | 465.97 Thousand USD | -125.678% |
| PharmChem, Inc. | 6.01 Million USD | 82.51% |
| Proteome Sciences plc | 6.4 Million USD | 83.571% |
| Response Genetics, Inc | 18.04 Million USD | 94.171% |
| Rennova Health, Inc. | 13.03 Million USD | 91.933% |
| RushNet, Inc. | 1.78 Million USD | 41.182% |
| ScreenPro Security Inc. | 1.91 Million USD | 45.061% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 72.291% |
| Todos Medical Ltd. | 7.69 Million USD | 86.334% |